Amphotericin B intralipid formulation: stability and particle size.
Amphotericin B remains the drug of choice for treating systemic fungal infections, although toxicity limits its clinical use. Some studies reported the use of Intralipid deoxycholate amphotericin B as an alternative delivery system. An in-vitro study was performed to assess the compatibility of deoxycholate amphotericin B in Intralipid. With two types of dilution of deoxycholate amphotericin B (in 5% dextrose and Intralipid or in Intralipid alone) the solution stability was not constant with a clear yellow precipitate. We observed an increase in the size of the particles (1.5-4-fold). In light of these results Intralipid deoxycholate amphotericin B should not be routinely administered.
Ranchère
J Y
JY
Department of Anesthesiology, Cancer Center Léon Bérard, Lyon, France.
Latour
J F
JF
Fuhrmann
C
C
Lagallarde
C
C
Loreuil
F
F
D000666:Amphotericin B / Q000737:chemistry*; D000900:Anti-Bacterial Agents / Q000737:chemistry; D000935:Antifungal Agents / Q000737:chemistry; D011232:Chemical Precipitation; D004355:Drug Stability; D005217:Fat Emulsions, Intravenous / Q000737:chemistry*; D009994:Osmolar Concentration; D013594:Syringes; D013997:Time Factors
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D005217:Fat Emulsions, Intravenous; D000666:Amphotericin B